Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11933MR)

This product GTTS-WQ11933MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11933MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4505MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ1890MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ6070MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ15702MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ6352MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ901MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ4316MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ7602MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW